中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
2期
256-256,258
,共2页
艾司西酞普兰%莫沙比利%胃食管反流病%临床疗效
艾司西酞普蘭%莫沙比利%胃食管反流病%臨床療效
애사서태보란%막사비리%위식관반류병%림상료효
Escitalopram%Moshabili%Gastroesophageal reflux disease%Clinical curative effect
目的：探讨艾司西酞普兰联合莫沙比利在胃食管反流病患者中的应用及效果。方法：选取我院自2010年5月~2011年5月消化内科收治的90例胃食管反流病患者为研究对象,随机将其分为A组和B组,观察并比较患者的疗效和药物不良反应。结果：B组患者治疗总有效率显著高于A组的(95.56%vs 82.22%,P<0.05),两组患者均未见显著的药物不良反应出现。结论：艾司西酞普兰联合莫沙比利能够有效改善胃食管反流病患者的临床症状,且无显著的药物不良反应,安全高效。
目的：探討艾司西酞普蘭聯閤莫沙比利在胃食管反流病患者中的應用及效果。方法：選取我院自2010年5月~2011年5月消化內科收治的90例胃食管反流病患者為研究對象,隨機將其分為A組和B組,觀察併比較患者的療效和藥物不良反應。結果：B組患者治療總有效率顯著高于A組的(95.56%vs 82.22%,P<0.05),兩組患者均未見顯著的藥物不良反應齣現。結論：艾司西酞普蘭聯閤莫沙比利能夠有效改善胃食管反流病患者的臨床癥狀,且無顯著的藥物不良反應,安全高效。
목적：탐토애사서태보란연합막사비리재위식관반류병환자중적응용급효과。방법：선취아원자2010년5월~2011년5월소화내과수치적90례위식관반류병환자위연구대상,수궤장기분위A조화B조,관찰병비교환자적료효화약물불량반응。결과：B조환자치료총유효솔현저고우A조적(95.56%vs 82.22%,P<0.05),량조환자균미견현저적약물불량반응출현。결론：애사서태보란연합막사비리능구유효개선위식관반류병환자적림상증상,차무현저적약물불량반응,안전고효。
Objective:To investigate the combined Mosa Billy of escitalopram in gastroesophageal reflux disease patients and its effect.Methods:In our hospital from 2010 May to 2011 May digestion Department of internal medicine treated 90 cases of patients with gastroesophageal reflux disease as the object of study,randomly divided into A group and B group,observe and compare the curative effect and adverse drug reaction.Results:The patients in the B group total effective rate (95.56%) was significantly higher than that in A group (82.22%),the total efficiency of the differences were statistically significant (P<0.05),two groups of patients had no obvious adverse drug reaction.Conclusion:Citalopram combined with Mosa Billy can effectively improve gastroesophageal reflux disease in patients with clinical symptoms,and no obvious adverse drug reaction,safety and high efficiency.
